Log in

NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

$32.87
+1.81 (+5.83 %)
(As of 12/8/2019 03:36 AM ET)
Today's Range
$30.98
Now: $32.87
$32.87
50-Day Range
$26.46
MA: $30.36
$36.60
52-Week Range
$11.56
Now: $32.87
$36.84
Volume4,181 shs
Average Volume9,928 shs
Market Capitalization$1.05 billion
P/E Ratio10.96
Dividend YieldN/A
Beta2.06
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.02 million
Cash Flow$3.21 per share
Book Value$5.49 per share

Profitability

Net Income$92.07 million

Miscellaneous

Employees149
Market Cap$1.05 billion
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.


ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

How were ZEALAND PHARMA/S's earnings last quarter?

ZEALAND PHARMA/S (NASDAQ:ZEAL) released its earnings results on Thursday, November, 14th. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.18. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $7.50 million. View ZEALAND PHARMA/S's Earnings History.

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ZEALAND PHARMA/S.

What price target have analysts set for ZEAL?

5 equities research analysts have issued 1 year target prices for ZEALAND PHARMA/S's stock. Their forecasts range from $30.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $37.67 in the next year. This suggests a possible upside of 14.6% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.

What is the consensus analysts' recommendation for ZEALAND PHARMA/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.

Has ZEALAND PHARMA/S been receiving favorable news coverage?

Headlines about ZEAL stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the near future. View News Stories for ZEALAND PHARMA/S.

Who are some of ZEALAND PHARMA/S's key competitors?

What other stocks do shareholders of ZEALAND PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Radius Health (RDUS).

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the folowing people:
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
  • Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)
  • Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)
  • Lani Pollworth Morvan, Investor Relations & Communications Officer

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $32.87.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $1.05 billion and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.View Additional Information About ZEALAND PHARMA/S.

What is ZEALAND PHARMA/S's official website?

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  475
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Momentum Indicators

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel